This is a mechanism module, not a specific disease. It sits downstream of, and specializes, the lysosomal_substrate_accumulation module: the hub node "Lysosomal GAG Accumulation" is the GAG-specific instance of "lysosomal_substrate_accumulation#Lysosomal Substrate Accumulation". Disorder entries reference individual nodes via conforms_to (e.g., "mps_gag_storage#Heparan Sulfate-Driven Neuroinflammation" for a neuronopathic type, or "mps_gag_storage#Chondrocyte Keratan Sulfate Storage and Impaired Endochondral Ossification" for Morquio). The coherence rule the module encodes is that an MPS type switches whole arms ON or OFF according to its stored-GAG profile but never assigns contradictory modifiers within an arm; this is why lumping all MPS into one graph is incoherent (the central-neurodegeneration node would have to be both present and absent) and why splitting per gene is redundant (MPS IIIA-D, or IVA-B, share an identical arm set). Evidence is drawn from MPS reviews and primary studies documenting the GAG-specific arms; evidence_source is OTHER for cross-MPS reviews, MODEL_ORGANISM for the MPS III mouse-model studies, and IN_VITRO for the cultured neuron synaptic study. Key conformance targets: the hub "Lysosomal GAG Accumulation" and the three arm-entry nodes named above.
Lysosomal GAG Accumulation
central effector
Deficiency of a specific GAG-degrading lysosomal enzyme leaves a partially degraded glycosaminoglycan undegraded, so it accumulates within the lysosome. This is the GAG-specific instance of the central lysosomal-storage effector, and it is the branch point of the module: the chemical identity of the stored GAG (heparan sulfate, dermatan sulfate, or keratan sulfate) determines which cell types store substrate and therefore which downstream arm is engaged. Undegraded GAG is not inert — it acts as a danger signal that engages the Toll-like receptor 4 innate-immune pathway, providing the molecular link from storage to the inflammatory and neuroinflammatory effectors of the arms below.
Downstream
-
Heparan Sulfate-Driven Neuroinflammation
When heparan sulfate is the stored GAG (MPS I, II, III, VII), it accumulates in neurons and microglia and engages the neuronopathic arm.
-
Dermatan Sulfate-Driven Connective-Tissue and ECM Storage
When dermatan sulfate is the stored GAG (MPS I, II, VI, VII), it accumulates in connective-tissue fibroblasts and ECM and engages the somatic arm.
-
Chondrocyte Keratan Sulfate Storage and Impaired Endochondral Ossification
When keratan sulfate is the stored GAG (MPS IV), it accumulates in chondrocytes and engages the skeletal-dysplasia arm.
Show evidence (2 references)
"Mucopolysaccharidoses are rare paediatric lysosomal storage disorders, characterised by accumulation of glycosaminoglycans within lysosomes"
Defines intralysosomal GAG accumulation as the characterizing event of the mucopolysaccharidoses, the central effector and branch hub of this module. Evidence source is OTHER because this is a cross-MPS review.
"We propose a model whereby progressive accumulation of glycosaminoglycans elicits an innate immune response, initiated by the Toll-like receptor 4 pathway"
Provides the molecular mechanism linking GAG storage to the downstream inflammatory and neuroinflammatory arms: undegraded GAG engages the Toll-like receptor 4 innate-immune pathway. Evidence source is OTHER because this is a review proposing a cross-MPS model.
Heparan Sulfate-Driven Neuroinflammation
effector
Undegraded heparan sulfate accumulates in neurons and microglia and triggers a neuroinflammatory cascade. This arm is engaged only by heparan sulfate-storing types; it is the entry node of the neuronopathic arm and the mechanistic reason heparan sulfate accumulation, uniquely among the GAGs, produces central nervous system disease.
Downstream
-
Synaptic Dysfunction and Secondary Storage
Neuroinflammation and accumulating heparan-sulfate oligosaccharides disrupt synaptic components and drive secondary metabolite storage.
Show evidence (3 references)
"Enzyme deficiency results in accumulation of partially degraded HS within lysosomes throughout the body, leading to a progressive severe neurological disease."
Establishes that heparan sulfate (HS) accumulation specifically produces progressive neurological disease, defining the neuronopathic arm. Evidence source is MODEL_ORGANISM because this paper reports an MPS IIIA mouse model study.
"The lack of functional enzyme in MPS IIIB patients leads to the progressive accumulation of heparan sulfate throughout the body and triggers a cascade of neuroinflammatory and other biochemical processes ultimately resulting in severe mental impairment and early death in adolescence or young adulthood."
Documents the conserved heparan-sulfate -> neuroinflammatory cascade -> mental impairment progression of the neuronopathic arm. Evidence source is MODEL_ORGANISM because this paper reports an MPS IIIB mouse model study.
"We propose a model whereby progressive accumulation of glycosaminoglycans elicits an innate immune response, initiated by the Toll-like receptor 4 pathway"
Cross-MPS human review providing non-model-organism support for the heparan-sulfate -> innate-immune/neuroinflammation link, so the neuroinflammation node is not supported by animal-model evidence alone. Evidence source is OTHER because this is a review synthesizing data across the mucopolysaccharidoses.
Synaptic Dysfunction and Secondary Storage
amplifier
Heparan-sulfate oligosaccharides and the neuroinflammatory milieu disrupt synaptic vesicle proteins and synaptic signalling, and drive secondary accumulation of gangliosides (GM2/GM3) in neurons. This amplifies primary storage into functional neuronal failure.
Downstream
-
Progressive Central Neurodegeneration
Sustained neuroinflammation and synaptic failure culminate in progressive neuronal loss.
Show evidence (1 reference)
"Clearance of heparan sulfate oligosaccharides in cultured embryonic MPSIIIB cortical neurons or treatment with proteasome inhibitors restored normal synaptophysin levels indicating that heparan sulfate oligosaccharides activate the degradation of synaptophysin by the proteasome with consequences..."
Shows mechanistically that heparan sulfate oligosaccharides drive degradation of the synaptic vesicle protein synaptophysin, linking storage to synaptic dysfunction. Evidence source is IN_VITRO because this is a cultured cortical neuron study.
Progressive Central Neurodegeneration
consequence
Sustained heparan-sulfate storage, neuroinflammation and synaptic failure produce progressive neuronal loss, presenting clinically as developmental regression, intellectual disability and dementia. This is the terminal node of the neuronopathic arm and is absent in types that do not store heparan sulfate (MPS IV, VI, IX).
Show evidence (2 references)
"Mucopolysaccharidosis type IIIA (MPSIIIA) is an inherited lysosomal storage disease caused by deficiency of sulfamidase, resulting in accumulation of the glycosaminoglycan (GAG) heparan sulfate. It is characterized by severe progressive neurodegeneration, together with somatic alterations, which..."
Confirms that heparan sulfate accumulation produces severe progressive neurodegeneration (with only minor somatic involvement), the terminal node of the neuronopathic arm and the neuronopathic pole of the MPS spectrum. Evidence source is MODEL_ORGANISM because this paper reports an MPS IIIA mouse model study.
"progressive build-up of sugars may lead to musculoskeletal abnormalities and multi-organ failure, and in others, to cognitive decline"
Cross-MPS human review providing non-model-organism support for progressive cognitive decline, so the neurodegeneration node is not supported by animal-model evidence alone. Evidence source is OTHER because this is a review synthesizing data across the mucopolysaccharidoses.
Dermatan Sulfate-Driven Connective-Tissue and ECM Storage
effector
Undegraded dermatan sulfate accumulates in connective-tissue fibroblasts and the extracellular matrix of bone, heart valve, cornea and viscera. This is the entry node of the somatic arm and produces the connective-tissue phenotype shared by the somatic MPS types: dysostosis multiplex, valvular thickening, corneal clouding and hepatosplenomegaly. It is engaged by dermatan sulfate-storing types and does not by itself produce central neurodegeneration.
Used by disorders
Sly syndrome
as Dermatan sulfate-driven connective-tissue storage
Downstream
-
Multisystem Somatic Disease
Progressive connective-tissue and ECM storage culminates in multi-organ and airway disease.
Show evidence (2 references)
"A prominent clinical manifestation of MPS-IH is dysostosis multiplex, a constellation of skeletal abnormalities."
Documents dysostosis multiplex, the hallmark connective-tissue/skeletal output of dermatan-sulfate storage, defining the somatic arm. Evidence source is OTHER because this is an MPS I review.
"due to the accumulation of storage material in tissues and organs, leading to cellular dysfunction, they progressively develop profound skeletal and joint abnormalities"
Links tissue/organ storage to progressive skeletal and joint disease, the conserved somatic-arm progression. Evidence source is OTHER because this is a review.
Multisystem Somatic Disease
consequence
Accumulated connective-tissue and ECM storage produces progressive multisystem somatic disease: musculoskeletal abnormalities, cardiac valve and respiratory/airway disease, and organomegaly. This is the terminal node of the somatic arm.
Show evidence (1 reference)
"progressive build-up of sugars may lead to musculoskeletal abnormalities and multi-organ failure, and in others, to cognitive decline"
Documents progression of GAG storage to musculoskeletal and multi-organ disease, the terminal node of the somatic arm. Evidence source is OTHER because this is a cross-MPS review.
Chondrocyte Keratan Sulfate Storage and Impaired Endochondral Ossification
effector
Undegraded keratan sulfate (with chondroitin-6-sulfate) accumulates preferentially in chondrocytes and cartilage extracellular matrix, impairing endochondral ossification and chondrogenesis. This is the entry node of the skeletal-dysplasia arm, engaged specifically by keratan sulfate-storing types (MPS IV / Morquio). Critically, this arm produces a different storage cell and a different outlet from the somatic arm and carries no primary neurodegeneration.
Used by disorders
Morquio syndrome
as Cartilage matrix dysfunction and impaired endochondral ossification
Downstream
-
Skeletal Dysplasia and Craniovertebral Instability
Impaired endochondral ossification produces a generalized skeletal dysplasia with mechanical craniovertebral instability.
Show evidence (2 references)
"Consequently, partially degraded GAG, chondroitin 6-sulfate (CS) and keratan sulfate (KS), accumulate in the lysosomes of affected cells, primarily in cartilage resulting in skeletal disease."
Establishes that keratan sulfate storage is restricted primarily to cartilage and produces skeletal rather than neuronopathic disease, defining the skeletal-dysplasia arm. Evidence source is OTHER because this is an MPS IVA review.
"As a result, partially degraded GAGs accumulate in bone, ligaments, and cartilage, as well as the extracellular matrix (ECM) of these tissues, impeding endochondral ossification and chondrogenesis"
Documents the specific mechanism of the skeletal arm: cartilage/ECM GAG storage impeding endochondral ossification and chondrogenesis. Evidence source is OTHER because this is an MPS IVA review.
Skeletal Dysplasia and Craniovertebral Instability
consequence
Impaired endochondral ossification produces a generalized skeletal dysplasia (disproportionate short stature, kyphoscoliosis, pectus carinatum, genu valgum, joint laxity) and odontoid hypoplasia with C1-C2 craniovertebral instability. Resulting cervical cord compression is mechanical and secondary, not a primary storage neurodegeneration — distinguishing this arm's neurological signs from the neuronopathic arm. This is the terminal node of the skeletal-dysplasia arm.
Show evidence (2 references)
"The accumulation of these GAGs leads to distinguishing features as skeletal dysplasia with disproportionate dwarfism, short neck, kyphoscoliosis, pectus carinatum, tracheal obstruction, coxa valga, genu valgum, and joint laxity."
Documents the skeletal-dysplasia phenotype that is the terminal output of the keratan-sulfate arm. Evidence source is OTHER because this is an MPS IVA review.
"Examination of the tissues demonstrated systemic storage materials in multiple tissues, as well as severely ballooned and vacuolated chondrocytes in the trachea, humerus, knee cartilage, and lung bronchus."
Confirms that the storage cell of this arm is the chondrocyte (ballooned and vacuolated), grounding the cell-type substitution. Evidence source is OTHER because this is an MPS IVA review.